Equities research analysts expect BIOLINERX LTD/S (NASDAQ:BLRX) to report ($0.06) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for BIOLINERX LTD/S’s earnings. BIOLINERX LTD/S reported earnings per share of ($0.07) during the same quarter last year, which suggests a positive year over year growth rate of 14.3%. The company is expected to announce its next quarterly earnings results on Tuesday, March 5th.

On average, analysts expect that BIOLINERX LTD/S will report full year earnings of ($0.22) per share for the current financial year. For the next financial year, analysts forecast that the business will report earnings of ($0.25) per share. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for BIOLINERX LTD/S.

Several research firms recently weighed in on BLRX. HC Wainwright set a $4.00 target price on BIOLINERX LTD/S and gave the stock a “buy” rating in a research report on Monday, October 22nd. Zacks Investment Research upgraded BIOLINERX LTD/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 7th. Maxim Group reiterated a “buy” rating and set a $2.00 target price on shares of BIOLINERX LTD/S in a research report on Thursday, November 8th. Finally, Oppenheimer set a $3.00 price objective on BIOLINERX LTD/S and gave the stock a “buy” rating in a report on Friday, November 9th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. BIOLINERX LTD/S currently has a consensus rating of “Buy” and an average target price of $2.50.

NASDAQ BLRX remained flat at $$0.41 during trading hours on Thursday. The company had a trading volume of 698,919 shares, compared to its average volume of 1,580,873. BIOLINERX LTD/S has a 1 year low of $0.38 and a 1 year high of $1.84. The stock has a market capitalization of $42.88 million, a P/E ratio of -1.50 and a beta of 1.84.

Several institutional investors have recently added to or reduced their stakes in the company. Two Sigma Securities LLC purchased a new position in shares of BIOLINERX LTD/S in the 4th quarter worth about $25,000. Menta Capital LLC purchased a new position in shares of BIOLINERX LTD/S in the 4th quarter worth about $33,000. ETF Managers Group LLC raised its holdings in shares of BIOLINERX LTD/S by 79.4% in the 4th quarter. ETF Managers Group LLC now owns 375,909 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 166,386 shares during the period. Finally, Fosun International Ltd purchased a new position in shares of BIOLINERX LTD/S in the 3rd quarter worth about $1,412,000. Institutional investors own 36.11% of the company’s stock.

About BIOLINERX LTD/S

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Featured Article: Why is cost of goods sold important?

Get a free copy of the Zacks research report on BIOLINERX LTD/S (BLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BIOLINERX LTD/S (NASDAQ:BLRX)

Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.